Rickard Malmström

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: BIOMEDICINE & PHARMACOTHERAPY. 2024;180:117613
Apixaban trough concentrations in atrial fibrillation patients with reduced renal function.
Al-Aieshy F; Skeppholm M; Fyrestam J; Johansson F; Pohanka A; Malmström RE
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2024;80(9):1343-1354
Apixaban plasma concentrations in patients with obesity
Al-Aieshy F; Skeppholm M; Fyrestam J; Johansson F; Pohanka A; Malmstrom RE
Article: JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE. 2022;9(7):205
Biological Variation in Rotational Thromboelastometry in Patients with Atrial Fibrillation Receiving Rivaroxaban
Mijovski MB; Antovic JP; Malmstrom RE; Mavri A
Article: CELLULAR AND MOLECULAR LIFE SCIENCES. 2022;79(5):247
Platelets fine-tune effector responses of naive CD4⁺ T cells via platelet factor 4-regulated transforming growth factor β signaling
Min Y; Hao L; Liu X; Tan S; Song H; Ni H; Sheng Z; Jooss N; Liu X; Malmstrom RE; Sun Y; Liu J; Tang H; Zhang H; Ma C; Peng J; Hou M; Li N
Article: PLATELETS. 2022;33(3):360-370
Platelets enhance CD4+central memory T cell responses via platelet factor 4-dependent mitochondrial biogenesis and cell proliferation
Tan S; Zhang J; Sun Y; Gistera A; Sheng Z; Malmstrom RE; Hou M; Peng J; Ma C; Liao W; Li N
Article: INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY. 2022;44(1):163-167
Using a low-molecular weight heparin-calibrated anti-factor Xa assay to assess the concentration of apixaban and rivaroxaban
von Horn H; Rasmusson A; Soderblom L; Malmstrom RE; Antovic J
Article: SCIENTIFIC REPORTS. 2021;11(1):13908
Apixaban concentration variability and relation to clinical outcomes in real-life patients with atrial fibrillation
Mavri A; Vene N; Bozic-Mijovski M; Miklic M; Soderblom L; Pohanka A; Malmstrom RE; Antovic J
Article: SCIENTIFIC REPORTS. 2021;11(1):5920
The in vitro addition of idarucizumab to plasma samples from patients increases thrombin generation
Mijovski MB; Malmstroem RE; Vene N; Antovic JP; Mavri A
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2021;77(3):409-419
Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants-a Swedish, register-based cohort study in atrial fibrillation outpatients
Holm J; Mannheimer B; Malmstrom RE; Eliasson E; Lindh JD
Article: JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 2020;18(10):2685-2700
Platelet factor 4 enhances CD4⁺T effector memory cell responses via Akt-PGC1α-TFAM signaling-mediated mitochondrial biogenesis
Tan S; Li S; Min Y; Gistera A; Moruzzi N; Zhang J; Sun Y; Andersson J; Malmstrom RE; Wang M; Berggren P-O; Schlisio S; Liao W; Ketelhuth DFJ; Ma C; Li N
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2020;76(6):867-876
Risk factors for severe bleeding events during warfarin treatment: the influence of sex, age, comorbidity and co-medication
Rydberg DM; Linder M; Malmstrom RE; Andersen M
Article: BLOOD COAGULATION & FIBRINOLYSIS. 2020;31(4):243-252
Effects of rivaroxaban and dabigatran on global hemostasis in patients with atrial fibrillation
Petkovic A; Al-Khalili F; Antovic A; Ammar M; Pruner I; Vranic A; Soutari N; Zdravkovic N; Malmstrom RE; Jakovljevic V; Antovic JP
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2019;75(8):1069-1075
Intra- and inter- individual rivaroxaban concentrations and potential bleeding risk in patients with atrial fibrillation
Miklic M; Mavri A; Vene N; Soderblom L; Bozic-Mijovski M; Pohanka A; Antovic J; Malmstrom RE
Article: APPLIED HEALTH ECONOMICS AND HEALTH POLICY. 2019;17(1):93-101
Did we see it Coming? An Evaluation of the Swedish Early Awareness and Alert System
Eriksson I; von Euler M; Malmstrom RE; Godman B; Wettermark B
Article: JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 2018;16(12):2462-2470
Rapid determination of anticoagulating effects of dabigatran in whole blood with rotational thromboelastometry and a thrombin-based trigger
Taune V; Skeppholm M; Agren A; Gryfelt G; Malmstrom RE; Wikman A; Van Ryn J; Wallen H
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2018;74(9):1165-1173
Sex differences in spontaneous reports on adverse drug events for common antihypertensive drugs
Rydberg DM; Mejyr S; Loikas D; Schenck-Gustafsson K; von Euler M; Malmstrom RE
Journal article: EUROPEAN HEART JOURNAL. 2018;39(suppl_1):ehy563.p4819
P4819Rapid determination of the anticoagulant effects of dabigatran in whole blood using ROTEM and a thrombin-based trigger
Taune V; Skeppholm M; Agren A; Gryfelt G; Malmstrom RE; Wikman A; Wallen H
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2018;74(5):663-670
The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations
Eriksson I; Komen J; Piehl F; Malmstrom RE; Wettermark B; von Euler M
Article: JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 2018;16(4):791-801
Thrombin-reduced miR-27b attenuates platelet angiogenic activities in vitro via enhancing platelet synthesis of anti-angiogenic thrombospondin-1
Miao X; Rahman MF-U; Jiang L; Min Y; Tan S; Xie H; Lee L; Wang M; Malmstrom RE; Lui W-O; Li N
Article: BMC HEALTH SERVICES RESEARCH. 2018;18(1):176
Patients' knowledge and attitudes to the Wise List - a drug formulary from the Stockholm Drug and Therapeutic committee
Bastholm-Rahmner P; Gustafsson LL; Aggefors K; Ateva K; Elfving S; Eriksen J; Jirlow M; Juhasz-Haverinen M; Malmstrom RE; Nikpour-Ardaly M; Rojvall M; Vallin M; Andersen-Karlsson E; Ovesjo M-L
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2018;103(3):493-501
Effectiveness of Drugs in Routine Care: A Model for Sequential Monitoring of New Medicines Using Dronedarone as Example
Cars T; Lindhagen L; Malmstrom RE; Neovius M; Schwieler J; Wettermark B; Sundstrom J
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2018;74(2):219-226
Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study
Eriksson I; Cars T; Piehl F; Malmstrom RE; Wettermark B; von Euler M
Article: THROMBOSIS AND HAEMOSTASIS. 2017;117(9):1700-1704
Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting
Antovic A; Norberg E-M; Berndtsson M; Rasmuson A; Malmstrom RE; Skeppholm M; Antovic J
Journal article: CLINICAL THERAPEUTICS. 2017;39(8):e16
Sex Differences in Spontaneous Reports on Adverse Drug Events for Antihypertensive Drugs
Rydberg DM; Mejyr S; Loikas D; Schenck-Gustafsson K; von Euler M; Malmström RE
Article: THROMBOSIS RESEARCH. 2017;153:76-82
Whole blood coagulation assays ROTEM and T-TAS to monitor dabigatran treatment
Taune V; Wallen H; Agren A; Gryfelt G; Sjovik C; Wintler AM; Malmstrom RE; Wikman A; Skeppholm M
Journal article: INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE. 2017;33(S1):154-155
VP18 Early Awareness And Alert System In Sweden: History And Current Status
Eriksson I; Wettermark B; Persson M; Edström M; Godman B; Lindhé A; Malmström R; Ramström H; von Euler M; Bergkvist-Christensen A
Journal article: INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE. 2017;33(S1):79-80
PP022 New Models Are Needed To Optimize The Management Of New Medicines
Godman B; Diogene E; Fürst J; Garuoliene K; Guerra A; Joppi R; Malmström R; Oortwijn W; Selke G; Timoney A; Wettermark B
Article: ANNALS OF CLINICAL BIOCHEMISTRY. 2016;53(4):446-451
Diluted thrombin time reliably measures low to intermediate plasma dabigatran concentrations
Bozic-Mijovski M; Malmstrom RE; Malovrh P; Antovic JP; Vene N; Sinigoj P; Mavri A
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2016;72(6):671-679
Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation
Al-Aieshy F; Malmstrom RE; Antovic J; Pohanka A; Ronquist-Nii Y; Berndtsson M; Al-Khalili F; Skeppholm M
Article: JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 2016;14(5):1043-1053
A single test to assay warfarin, dabigatran, rivaroxaban, apixaban, unfractionated heparin, and enoxaparin in plasma
Letertre LR; Gudmundsdottir BR; Francis CW; Gosselin RC; Skeppholm M; Malmstrom RE; Moll S; Hawes E; Francart S; Onundarson PT
Article: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2015;117(5):323-329
Dabigatran Concentration: Variability and Potential Bleeding Prediction In "Real-Life" Patients With Atrial Fibrillationl
Sinigoj P; Malmstrom RE; Vene N; Roenquist-Nii Y; Bozic-Mijovski M; Pohanka A; Antovic JP; Mavri A
Journal article: GABI JOURNAL. 2015;4(3):125-135
Generic pregabalin; current situation and implications for health authorities, generics and biosimilars manufacturers in the future
Godman B; Wilcock M; Martin A; Bryson S; Baumgaertel C; Bochenek T; de Bruyn W; Brkicic LS; D'Agata M; Fogele A; Fuste AC; Fraeyman J; Fuerst J; Garuoliene K; Herholz H; Hoffmann M; Jayathissa S; Kwon H-Y; Langner I; Kalaba M; Karlsson EA; Laius O; Markovic-Pekovic V; Magnusson E; McTaggart S; Metcalfe S; Pedersen HB; Piessnegger J; Ringerud AM; Selke GW; Sermet C; Schiffers K; Skiold P; Slaby J; Tomek D; Viksna A; Vitry A; Zara C; Malmstrom RE
Article: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2015;15(5):755-758
Improving the managed introduction of new medicines: sharing experiences to aid authorities across Europe
Matusewicz W; Godman B; Pedersen HB; Fuerst J; Gulbinovic J; Mack A; Selke G; Timoney A; Warminska E; Malmstrom RE
Article: THROMBOSIS RESEARCH. 2015;136(1):148-153
Clinical evaluation of laboratory methods tomonitor apixaban treatment in patients with atrial fibrillation
Skeppholm M; Al-Aieshy F; Berndtsson M; Al-Khalili F; Ronquist-Nii Y; Soderblom L; Ostlund AY; Pohanka A; Antovic J; Malmstrom RE
Article: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2015;15(2):323-330
Quality and efficiency of statin prescribing across countries with a special focus on South Africa; findings and future implications
Godman B; Bishop I; Campbell SM; Malmstrom RE; Truter I
Article: PHARMACOTHERAPY. 2015;35(2):140-147
Differential Impact of Selective Serotonin Reuptake Inhibitors on Platelet Response to Clopidogrel: A Randomized, Double-Blind, Crossover Trial
Hirsh-Rokach B; Spectre G; Shai E; Lotan A; Ritter A; Al-Aieshy F; Malmstrom RE; Varon D; Alcalai R
Article: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2015;116(2):146-157
Quality Indicators as a Tool in Improving the Introduction of New Medicines
Campbell SM; Godman B; Diogene E; Fuerst J; Gustafsson LL; MacBride-Stewart S; Malmstrom RE; Pedersen H; Selke G; Vlahovic-Palcevski V; van Woerkom M; Wong-Rieger D; Wettermark B
Article: EXPERT REVIEW OF CLINICAL PHARMACOLOGY. 2015;8(1):77-94
Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?
Godman B; Malmstrom RE; Diogene E; Gray A; Jayathissa S; Timoney A; Acurcio F; Alkan A; Brzezinska A; Bucsics A; Campbell SM; Czeczot J; de Bruyn W; Eriksson I; Yusof FAM; Finlayson AE; Furst J; Garuoliene K; Guerra Junior A; Gulbinovic J; Jan S; Joppi R; Kalaba M; Magnisson E; McCullagh L; Miikkulainen K; Ofierska-Sujkowska G; Pedersen HB; Selke G; Sermet C; Spillane S; Supian A; Truter I; Vlahovic-Palcevski V; Vien LE; Vural EH; Wale J; Wladysiuk M; Zeng W; Gustafsson LL
Article: FRONTIERS IN PHARMACOLOGY. 2014;5:219
Different initiatives across Europe to enhance losartan utilization post generics: impact and implications
Moon JC; Godman B; Petzold M; Alvarez-Madrazo S; Bennett K; Bishop I; Bucsics A; Hesse U; Martin A; Simoens S; Zara C; Malmstrom RE
Article: THROMBOSIS RESEARCH. 2014;134(4):783-789
On the monitoring of dabigatran treatment in "real life" patients with atrial fibrillation
Skeppholm M; Hjemdahl P; Antovic JP; Muhrbeck J; Eintrei J; Ronquist-Nii Y; Pohanka A; Beck O; Malmstrom RE
Journal article: GABI JOURNAL. 2014;3(3):122-132
Ongoing initiatives to improve prescribing efficiency in China; statins as a case history
Zeng W; Xi H; Godman B; Finlayson AE; Malmstrom RE
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2014;70(1):117-126
Sex differences in spontaneous reports on adverse bleeding events of antithrombotic treatment
Rydberg DM; Holm L; Mejyr S; Loikas D; Schenck-Gustafsson K; von Euler M; Wettermark B; Malmstrom RE
Journal article: APPLIED HEALTH ECONOMICS AND HEALTH POLICY. 2013;11(6):677-685
Impact of Delisting ARBs, Apart from Losartan, on ARB Utilisation Patterns in Denmark: Implications for Other Countries
Hesse U; Godman B; Petzold M; Martin A; Malmstrom RE
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2013;69(11):1875-1881
Evaluation of coagulation assays versus LC-MS/MS for determinations of dabigatran concentrations in plasma
Antovic JP; Skeppholm M; Eintrei J; Boija EE; Soderblom L; Norberg E-M; Onelov L; Ronquist-Nii Y; Pohanka A; Beck O; Hjemdahl P; Malmstrom RE
Article: DISEASES OF THE ESOPHAGUS. 2013;26(8):853-858
Nitric oxide and endothelin-1 release after one-lung ventilation during thoracoabdominal esophagectomy
Lund M; Ny L; Malmstrom RE; Lundberg JO; Ost A; Bjornstedt M; Lundell L; Tsai JA
Journal article: JOURNAL OF PHARMACEUTICAL HEALTH SERVICES RESEARCH. 2013;4(3):173-181
Measures to enhance angiotensin-receptor blocker prescribing efficiency in Belgium following generic losartan: impact and implications for the future
Simoens S; De Bruyn K; Miranda J; Bennie M; Malmstrom RE; Godman B
Article: INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. 2013;67(9):853-862
Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries
Godman B; Wettermark B; Miranda J; Bennie M; Martin A; Malmstrom RE
Article: THROMBOSIS AND HAEMOSTASIS. 2013;110(3):543-549
Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate
Douxfils J; Dogne J-M; Mullier F; Chatelain B; Ronquist-Nii Y; Malmstrom RE; Hjemdahl P
Journal article: EUROPEAN HEART JOURNAL. 2013;34(suppl_1):5854
Methods to monitor dabigatran: first clinical experience in patients with atrial fibrillation
Skeppholm M; Muhrbeck J; Antovic JP; Eintrei J; Ronquist-Nii Y; Pohanka A; Beck O; Hjemdahl P; Malmstrom RE
Journal article: CLINICAL THERAPEUTICS. 2013;35(8):e43-e44
PP083—Dabigatran– demonstrates the need for comprehensive approaches to optimise the use of new drugs
Malmstrom RE; Godman B; Diogene E; Bennie M; Furst J; Gutiérrez-Ibarluzea I; McCullagh L; Vlahovic-Palcevski V; Gustafsson LL
Article: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2013;112(6):392-400
Extraction of Electronic Health Record Data in a Hospital Setting: Comparison of Automatic and Semi-Automatic Methods Using Anti-TNF Therapy as Model
Cars T; Wettermark B; Malmstrom RE; Ekeving G; Vikstrom B; Bergman U; Neovius M; Ringertz B; Gustafsson LL
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2013;69:S25-S32
Therapeutic drug monitoring for tomorrow
Eliasson E; Lindh JD; Malmstrom RE; Beck O; Dahl M-L
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2013;69:73-78
Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations
Bjorkhem-Bergman L; Andersen-Karlsson E; Laing R; Diogene E; Melien O; Jirlow M; Malmstrom RE; Vogler S; Godman B; Gustafsson LL
Article: FRONTIERS IN PHARMACOLOGY. 2013;4:39
Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs
Malmstrom RE; Godman BB; Diogene E; Baumgartel C; Bennie M; Bishop I; Brzezinska A; Bucsics A; Campbell S; Ferrario A; Finlayson AE; Furst J; Garuoliene K; Gomes M; Gutierrez-Ibarluzea I; Haycox A; Hviding K; Herholz H; Hoffmann M; Jan S; Jones J; Joppi R; Kalaba M; Kvalheim C; Laius O; Langner I; Lonsdale J; Loov S-A; Malinowska K; McCullagh L; Paterson K; Markovic-Pekovic V; Martin A; Piessnegger J; Selke G; Sermet C; Simoens S; Tulunay C; Tomek D; Voncina L; Vlahovic-Palcevski V; Wale J; Wilcock M; Wladysiuk M; van Woerkom M; Zara C; Gustafsson LL
Article: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2012;12(6):809-819
Influence of lifting prescribing restrictions for losartan on subsequent sartan utilization patterns in Austria: implications for other countries
Bucsics A; Godman B; Burkhardt T; Schmitzer M; Malmstrom RE
Article: JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH. 2012;1(6):539-549
Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history?
Kalaba M; Godman B; Vuksanovic A; Bennie M; Malmstrom RE
Article: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2012;12(4):439-441
Improving the managed entry of new medicines: sharing experiences across Europe
Godman B; Paterson K; Malmstrom RE; Selke G; Fagot J-P; Mrak J
Journal article: GABI JOURNAL. 2012;1(2):58-68
What lessons can be learned from the launch of generic clopidogrel?
Baumgartel C; Godman B; Malmstrom RE; Andersen M; Abuelkhair M; Abdu S; Bennie M; Bishop I; Burkhardt T; Fahmy S; Furst J; Garuoliene K; Herholz H; Kalaba M; Koskinen H; Laius O; Lonsdale J; Malinowska K; Ringerud AM; Schwabe U; Sermet C; Skiold P; Teixeira I; van Woerkom M; Vitry A; Voncina L; Zara C; Gustafsson LL
Journal article: GABI JOURNAL. 2012;1(2):69-83
Payers endorse generics to enhance prescribing efficiency: impact and future implications, a case history approach
Godman B; Abuelkhair M; Vitry A; Abdu S; Bennie M; Bishop I; Fahmy S; Garuoliene K; Herholz H; Martin A; Malmstrom RE; Jan S; Schwabe U; Sermet C; Skiold P; Voncina L; Gustaffson LL
Article: EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH. 2012;12(1):115-124
Imperative to consider multiple initiatives to maximize prescribing efficiency from generic availability: case history from Abu Dhabi
Abuelkhair M; Abdu S; Godman B; Fahmy S; Malmstrom RE; Gustafsson LL
Journal article: REVIEWS IN HEALTH CARE. 2011;3(1):5-16
Prescribing restrictions – a necessary strategy among some European countries to enhance future prescribing efficiency?
Godman B; Malmström R; Bennie M; Sakshaug S; Burkhardt T; Campbell S; Garuoliene K; Schwabe U; Vončina L; Gustafsson LL
Article: LAKARTIDNINGEN. 2011;108(36):1664-1665
[Say no to the extremes in the debate on lipid reduction].
Hjemdahl P; Allhammar A; Eklund J; Forslund T; Hulting J; Kahan T; Martinsson A; Malmström R; Rücker F; Schenck-Gustafsson K; Schwieler J; Törnerud M; Wettermark B
Journal article: EUROPEAN JOURNAL OF ANAESTHESIOLOGY. 2010;27(1):92
Nitric oxide and endothelin-1 release after one-lung ventilation during thoracoabdominal oesophagectomy
Lund M; Ny L; Malmstrm R; Lundell L; Tsai J
Article: ACTA PHYSIOLOGICA. 2010;198(4):441-448
Endothelin attenuates endothelium-dependent platelet inhibition in man
Malmstrom RE; Settergren M; Pernow J
Article: FRONTIERS IN PHARMACOLOGY. 2010;1:141
Policies to enhance prescribing efficiency in Europe: findings and future implications
Godman B; Shrank W; Andersen M; Berg C; Bishop I; Burkhardt T; Garuoliene K; Herholz H; Joppi R; Kalaba M; Laius O; Lonsdale J; Malmstrom RE; Martikainen JE; Samaluk V; Sermet C; Schwabe U; Teixeira I; Tilson L; Tulunay FC; Vlahovic-Palcevski V; Wendykowska K; Wettermark B; Zara C; Gustafsson LL
Journal article: LAKARTIDNINGEN. 2009;106(45):3019-3020
[New drug in atrial fibrillation--how does it function in regular health care?].
Holmström M; Johnsson H; Lärfars G; Malmström R; Hjemdahl P
Article: JOURNAL OF INTERNAL MEDICINE. 2009;266(5):457-466
Influence of statin treatment on platelet inhibition by clopidogrel - a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment
Malmstrom RE; Orstergren J; Jorgensen L; Hjemdahl P
Article: LAKARTIDNINGEN. 2009;106(32-33):1992-1994
[SBU should investigate what is an evidence-based and cost-effective use of statins].
Hjemdahl P; Allhammar A; Heaton C; Hulting J; Kahan T; Malmström R; Martinsson A; Rücker F; Schenck-Gustafsson K; Schwieler J; Törnerud M; Wettermark B
Article: ATHEROSCLEROSIS. 2009;204(1):73-78
L-Arginine and tetrahydrobiopterin protects against ischemia/reperfusion-induced endothelial dysfunction in patients with type 2 diabetes mellitus and coronary artery disease
Settergren M; Bohm F; Malmstrom RE; Channon KM; Pernow J
Article: THROMBOSIS AND HAEMOSTASIS. 2009;101(1):157-164
No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance
Malmstrom RE; Settergren M; Bohm F; Pernow J; Hjemdahl P
Journal article: LAKARTIDNINGEN. 2008;105(1-2):45
[Several cases of liver affected by aloe vera].
Belfrage B; Malmström R
Article: LAKARTIDNINGEN. 2005;102(22):1751-1752
[LFN's evaluation of Inspra illustrates the need of drug committees!].
Malmström R; Hjemdahl P
Article: AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. 2003;168(1):114-120
Endogenous nitric oxide release by vasoactive drugs monitored in exhaled air
Malmström RE; Törnberg DC; Settergren G; Liska J; Angdin M; Lundberg JO; Weitzberg E
Article: SHOCK. 2002;18(5):456-460
Intestinal nitric oxide in the normal and endotoxemic pig
Malmström RE; Björne H; Oldner A; Wanecek M; Fredriksson M; Lundberg JON; Weitzberg E
Article: EUROPEAN JOURNAL OF PHARMACOLOGY. 2002;439(1-3):113-119
Autoinhibitory function of the sympathetic prejunctional neuropeptide YY₂ receptor evidenced by BIIE0246
Malmström RE; Lundberg JON; Weitzberg E
Article: NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY. 2002;365(2):106-111
Effects of the neuropeptide YY2 receptor antagonist BIIE0246 on sympathetic transmitter release in the pig in vivo
Malmström RE; Lundberg JON; Weitzberg E
Article: LIFE SCIENCES. 2001;69(17):1999-2005
Existence of both neuropeptide Y, Y1 and Y2 receptors in pig spleen: evidence using subtype-selective antagonists in vivo.
Malmström RE
Article: BRITISH JOURNAL OF PHARMACOLOGY. 2001;133(7):1073-1080
Vascular pharmacology of BIIE0246, the first selective non-peptide neuropeptide Y Y(2) receptor antagonist, in vivo.
Malmström RE
Article: EUROPEAN JOURNAL OF PHARMACOLOGY. 2001;418(1-2):95-104
Pharmacology of H 394/84, a dihydropyridine neuropeptide Y Y(1) receptor antagonist, in vivo.
Malmström RE; Balmér KC; Weilitz J; Nordlander M; Sjölander M
Article: NITRIC OXIDE-BIOLOGY AND CHEMISTRY. 2001;5(2):98-104
Nitric oxide inhibition of renal vasoconstrictor responses to sympathetic cotransmitters in the pig in vivo
Malmström RE; Bjorne H; Alving K; Weitzberg E; Lundberg JON
Article: REGULATORY PEPTIDES. 2000;95(1-3):59-63
Neuropeptide Y Y1 receptor mediated mesenteric vasoconstriction in the pig in vivo.
Malmström RE
Article: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2000;36(4):516-525
In vivo characterization of the novel neuropeptide Y Y1 receptor antagonist H 409/22.
Malmström RE; Alexandersson A; Balmér KC; Weilitz J
Article: NEUROPEPTIDES. 1999;33(4):253-259
Vascular neuropeptide YY1-receptors in the rat kidney: vasoconstrictor effects and expression of Y1-receptor mRNA
Modin A; Malmström RE; Meister B
Article: REGULATORY PEPTIDES. 1998;75-6:55-70
Characterization and molecular cloning of vascular neuropeptide Y receptor subtypes in pig and dog
Malmström RE; Hökfelt T; Björkman JA; Nihlén C; Byström M; Ekstrand AJ; Lundberg JM
Article: ACTA PHYSIOLOGICA. 1997;161(3):327-338
Time-dependent effects of ischaemia on neuropeptide Y mechanisms in pig renal vascular control in vivo.
Malmström RE; Lundberg JM
Article: BRITISH JOURNAL OF PHARMACOLOGY. 1997;121(3):595-603
The neuropeptide Y (NPY) Y1 receptor antagonist BIBP 3226: equal effects on vascular responses to exogenous and endogenous NPY in the pig in vivo.
Malmström RE; Balmér KC; Lundberg JM
Article: EUROPEAN JOURNAL OF PHARMACOLOGY. 1996;318(2-3):369-376
Effects of Ro 47-0203 and PD155080 on the plasma kinetics, receptor binding and vascular effects of endothelin in the pig
Hemsen A; Modin A; Wanecek M; Malmstrom RE; Weitzberg E
Article: NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY. 1996;354(5):633-642
Effects of the neuropeptide YY1 receptor antagonist SR 120107A on sympathetic vascular control in pigs in vivo .
Malmström RE; Lundberg JM
Article: TRENDS IN PHARMACOLOGICAL SCIENCES. 1996;17(9):301-304
Recent developments with neuropeptide Y receptor antagonists
Lundberg JM; Modin A; Malmstrom RE
Article: EUROPEAN JOURNAL OF PHARMACOLOGY. 1996;305(1-3):145-154
SR 120107A antagonizes neuropeptide Y Y-1 receptor mediated sympathetic vasoconstriction in pigs in vivo
Malmstrom RE; Modin A; Lundberg JM
Article: EUROPEAN JOURNAL OF PHARMACOLOGY. 1995;294(2-3):661-668
Neuropeptide Y accounts for sympathetic vasoconstriction in guinea-pig vena cava: evidence using BIBP 3226 and 3435.
Malmstrom RE; Lundberg JM
Visa fler

Alla övriga publikationer

Review: APPLIED HEALTH ECONOMICS AND HEALTH POLICY. 2020;18(1):5-16
Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab
Pontes C; Zara C; Torrent-Farnell J; Obach M; Nadal C; Vella-Bonanno P; Ermisch M; Simoens S; Hauegen RC; Gulbinovic J; Timoney A; Martin AP; Mueller T; Nachtnebel A; Campbell S; Selke G; Bochenek T; Rothe CC; Mardare I; Bennie M; Furst J; Malmstrom RE; Godman B
Conference publication: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2019;75:S26-S27
Comparison of anti-FXa chromogenic assay for rivaroxaban used in North Estonia Medical Centre with LC-MS/MS
Arjakse J; Malmstrom R; Allvee M; Gustafsson L; Ilumets H; Kostjuk J; Mark M; Pikta M; Pohanka A; Ronquist Y; Marandi T
Review: FRONTIERS IN PUBLIC HEALTH. 2018;6:328
Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets
Godman B; Bucsics A; Bonanno PV; Oortwijn W; Rothe CC; Ferrario A; Bosselli S; Hill A; Martin AP; Simoens S; Kurdi A; Gad M; Gulbinovic J; Timoney A; Bochenek T; Salem A; Hoxha I; Sauermann R; Massele A; Guerra AAJ; Petrova G; Mitkova Z; Achniotou G; Laius O; Sermet C; Selke G; Kourafalos V; Yfantopoulos J; Magnusson E; Joppi R; Oluka M; Kwon H-Y; Jakupi A; Kalemeera F; Fadare JO; Melien O; Pomorski M; Wladysiuk M; Markovic-Pekovic V; Mardare I; Meshkov D; Novakovic T; Furst J; Tomek D; Zara C; Diogene E; Meyer JC; Malmstrom RE; Wettermark B; Matsebula Z; Campbell S; Haycox A
Conference publication: VALUE IN HEALTH. 2018;21:S183
EVALUATION OF THE SWEDISH EARLY AWARENESS AND ALERT SYSTEM
Eriksson I; von Euler M; Malmstrom R; Godman B; Wettermark B
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2018;27:214
Impact of new drugs and treatment recommendations on drug utilization in multiple sclerosis
Eriksson I; Komen J; Piehl F; Malmstrom RE; Wettermark B; von Euler M
Conference publication: EUROPEAN HEART JOURNAL. 2018;39:1014
Rapid determination of the anticoagulant effects of dabigatran in whole blood using ROTEM and a thrombin-based trigger
Taune V; Skeppholm M; Agren A; Gryfelt G; Malmstrom RE; Wikman A; Wallen H
Review: FRONTIERS IN PHARMACOLOGY. 2017;8:674
The Early Awareness and Alert System in Sweden: History and Current Status
Eriksson I; Wettermark B; Persson M; Edstrom M; Godman B; Lindhe A; Malmstrom RE; Ramstrom H; von Euler M; Christensen AB
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2017;26:381-382
Dronedarone and Hepatic Toxicity? A Model for Evaluation of Post-Marketing Safety of Drugs in Routine Care
Cars T; Lindhagen L; Malmstrom RE; Neovius M; Schwieler J; Wettermark B; Sundstrom J
Review: BMJ OPEN. 2017;7(4):e014345
High adherence to the 'Wise List' treatment recommendations in Stockholm: a 15-year retrospective review of a multifaceted approach promoting rational use of medicines
Eriksen J; Gustafsson LL; Ateva K; Bastholm-Rahmner P; Ovesjo M-L; Jirlow M; Juhasz-Haverinen M; Larfars G; Malmstrom RE; Wettermark B; Andersen-Karlsson E
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2016;25:504
An Automatized Model for Sequential Monitoring of Effectiveness of New Drugs Using Dronedarone as Example
Cars T; Neovius M; Lindhagen L; Malmstrom RE; Schwieler J; Wettermark B; Sundstrom J
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2016;25:3-4
Drug Utilization Patterns in Relapsing-Remitting Multiple Sclerosis: A Population-Based Cohort Study
Eriksson I; Cars T; Piehl F; Malmstrom R; Wettermark B; von Euler M
Conference publication: THROMBOSIS RESEARCH. 2016;141:S2
DABIGATRAN TROUGH AND PEAK LEVELS IN "REAL-LIFE" PATIENTS WITH ATRIAL FIBRILLATION
Sinigoj P; Malmstrom RE; Vene N; Bozic-Mijovski M; Pohanka A; Antovic JP; Mavri A
Conference publication: ACTA PHYSIOLOGICA. 2015;215:69
Novel oral anticoagulants and the clinical pharmacological/therapeutic aspect of therapeutic drug monitoring
Malmstrom RE
Meeting abstract: CLINICAL THERAPEUTICS. 2015;37(8):E168
SYSTEMATIC INTRODUCTION OF NEW THERAPIES WITHIN THE STOCKHOLM COUNTY AND THE KAROLINSKA UNIVERSITY HOSPITAL
Malmstrom RE; Stiller C-O
Conference publication: EUROPEAN HEART JOURNAL. 2015;36:687
Clinical evaluation of laboratory methods to monitor rivaroxaban treatment in patients with atrial fibrillation
Skeppholm M; Berndtsson M; Al-Khalili F; Ronquist-Nii Y; Pohanka A; Antovic J; Malmstrom RE
Conference publication: JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 2015;13:901
The dilute FIIX prothrombin time (DFIIX-PT) for assessment of dabigatran, rivaroxaban and warfarin effect in patient samples
Letertre L; Gudmundsdottir B; Skeppholm M; Malmstrom R; Francis CW; Onundarson P
Conference publication: JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 2015;13:638
Intra-individual variability in trough and peak dabigatran levels in "real-life" atrial fibrillation patients
Vene N; Sinigoj P; Malmstrom R; Ronquist-Nii Y; Bozic-Mijovski M; Pohanka A; Antovic J; Mavri A
Conference publication: JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 2015;13:396
Effects of new oral anticoagulants on fibrin-network permeability and thrombin generation
Skeppholm M; Zabczyk M; Al-Khalili F; Malmstrom R; Agren A; Blomback M; He S; Wallen H
Review: FRONTIERS IN PHARMACOLOGY. 2014;5:109
Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs
Godman B; Malmstrom RE; Diogene E; Jayathissa S; McTaggart S; Cars T; Alvarez-Madrazo S; Baumgaertel C; Brzezinska A; Bucsics A; Campbell S; Eriksson I; Finlayson A; Fuerst J; Garuoliene K; Gutierrez-Ibarluzea I; Hviding K; Herholz H; Joppi R; Kalaba M; Laius O; Malinowska K; Pedersen HB; Markovic-Pekovic V; Piessnegger J; Selke G; Sermet C; Spillane S; Tomek D; Voncina L; Vlahovic-Palcevski V; Wale J; Wladysiuk M; van Woerkom M; Zara C; Gustafsson LL
Meeting abstract: THROMBOSIS RESEARCH. 2014;133:S38-S39
IS THERE A ROLE FOR STANDARD THROMBIN TIME (TT) MEASUREMENTS FOR THE MONITORING OF LOW LEVELS OF DABIGATRAN?
Antovic JP; Berndtsson M; Malmstrom RE; Thalen S; Pohanka A; Norberg E-M; Ronquist Y; Hjemdahl P
Review: BMC MEDICINE. 2013;11:179
Personalizing health care: feasibility and future implications
Godman B; Finlayson AE; Cheema PK; Zebedin-Brandl E; Gutierrez-Ibarluzea I; Jones J; Malmstrom RE; Asola E; Baumgartel C; Bennie M; Bishop I; Bucsics A; Campbell S; Diogene E; Ferrario A; Fuerst J; Garuoliene K; Gomes M; Harris K; Haycox A; Herholz H; Hviding K; Jan S; Kalaba M; Kvalheim C; Laius O; Loeoev S-A; Malinowska K; Martin A; McCullagh L; Nilsson F; Paterson K; Schwabe U; Selke G; Sermet C; Simoens S; Tomek D; Vlahovic-Palcevski V; Voncina L; Wladysiuk M; van Woerkom M; Wong-Rieger D; Zara C; Ali R; Gustafsson LL
Conference publication: EUROPEAN HEART JOURNAL. 2013;34:1097
Methods to monitor dabigatran: first clinical experience in patients with atrial fibrillation
Skeppholm M; Muhrbeck J; Antovic JP; Eintrei J; Ronquist-Nii Y; Pohanka A; Beck O; Hjemdahl P; Malmstrom RE
Conference publication: JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 2013;11:834-835
Comparison of hemoclot thrombin inhibitor® and activated partial thromboplastin time with a reference UPLC-MS/MS method to monitor patients receiving dabigatran etexilate
Douxfils J; Hjemdahl P; Malmstrom RE; Ronquist Y; Beck O; Baudar J; J-F C; Chatelain C; Chatelain B; Mullier F; Dogne J-M
Book chapter: ESSENTIAL GUIDE TO BLOOD COAGULATION. 2013;p. 111-120
New oral anticoagulants: focus on currently approved oral factor Xa and thrombin inhibitors
Malmström RE; Johnsson H
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2012;21:175-176
Extraction of Electronic Health Record Data in a Hospital Setting: Comparison of Automatic and Semi-Automatic Methods Using Anti-TNF Therapy as Model
Cars T; Wettermark B; Ekeving G; Vikstrom B; Malmstrom R; Gustafsson LL; Bergman U; Neovius M; Ringertz B
Other: LAKARTIDNINGEN. 2011;108(47):2444-2445
[Visions are good but the guidelines require evidence].
Hjemdahl P; Allhammar A; Eklund J; Forslund T; Hulting J; Kahan T; Martinsson A; Malmström R; Rücker F; Schenck-Gustafsson K; Schwieler J; Törnerud M; Wettermark B
Conference publication: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2011;109:50
CRITICAL DRUG EVALUATION TO OPTIMISE THE MANAGED ENTRY OF NEW DRUGS
Malmstrom RE; Gustafsson LL
Conference publication: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2011;109:43
THE 'WISE LIST'-A COMPREHENSIVE CONCEPT TO SELECT, COMMUNICATE AND ACHIEVE ADHERENCE TO RECOMMENDATIONS OF ESSENTIAL DRUGS IN A METROPOLIAN HALTHCARE REGION
Gustafsson LL; Malmstrom R
Letter: THROMBOSIS RESEARCH. 2010;125(5):473-474
Poor performance with a platelet counting technique to monitor clopidogrel inhibitory effects in the point-of-care setting
Malmstrom RE; Ostergren J; Jorgensen L; Hjemdahl P
Book chapter: ESSENTIAL GUIDE TO BLOOD COAGULATION. 2009;p. 91-102
New Anticoagulants: Focus on Currently Approved Oral Factor Xa and Factor IIa Inhibitors
Malmström RE
Other: LAKARTIDNINGEN. 2009;106(40):2550-2551
[Lower and lower cholesterol targets increase adverse effects].
Hjemdahl P; Allhammar A; Heaton C; Hulting J; Kahan T; Malmström R; Martinsson A; Rücker F; Schenck-Gustafsson K; Schwieler J; Törnerud M; Wettermark B; Forfattarna utgör Läkemedelssakkunnigas (Läksak) e; Stockholms Iäns landsting
Editorial comment: THROMBOSIS AND HAEMOSTASIS. 2008;100(4):517-518
Dyspnea and antiplatelet drugs: Little cause for concern with clopidogrel
Malmstrom RE; Hjemdahl P
Conference publication: EUROPEAN HEART JOURNAL. 2008;29:714
L-arginine and tetrahydrobiopterin protects against ischemia/reperfusion-induced endothelial dysfunction in patients with type 2 diabetes mellitus and coronary artery disease
Settergren M; Bohm F; Malmstrom RE; Channon KM; Pernow J
Other: LAKARTIDNINGEN. 2008;105(22):1692
[A reply to Ake Sjoholm et al about new agents against type 2 diabetes: safety data prior to wide utilization or the other way round?].
Karlsson EA; Palmér M; Malmström R
Meeting abstract: ATHEROSCLEROSIS SUPPLEMENTS. 2008;9(1):205
LIPID LOWERING EFFICACY OF ROSUVASTATIN VS ATORVASTATIN IN PATIENTS WITH CORONARY ARTERY DISEASE
Ostergren J; Malmstrom R; Jorgensen L; Walldius G
Letter: LAKARTIDNINGEN. 2008;105(9):647-648
[Treatment with new preparations against type 2 diabetes not sufficiently documented].
Karlsson EA; Palmér M; Malmström R
Editorial comment: JOURNAL OF HYPERTENSION. 2004;22(1):27-29
Endothelin and nitric oxide in inflammation:: could there be a need for endothelin blocking anti-inflammatory drugs?
Malmström RE; Weitzberg E
Review: PROGRESS IN MEDICINAL CHEMISTRY. 2004;42:207-244
5. Neuropeptide Y receptor antagonists in cardiovascular pharmacology.
Malmström RE
Review: EUROPEAN JOURNAL OF PHARMACOLOGY. 2002;447(1):11-30
Pharmacology of neuropeptide Y receptor antagonists. Focus on cardiovascular functions.
Malmström RE
Doctoral thesis: 1997
Neuropeptide Y Y1 receptor mechanisms in sympathetic vascular control
Malmström RE
Book chapter: NEUROPEPTIDE Y AND DRUG DEVELOPMENT. 1997;p. 41-55
Chapter 3 Neuropeptide y in sympathetic nerves — evidence for Y1 receptor mediated vascular control
Malmström RE; Lundberg JM
Review: ACTA PHYSIOLOGICA SCANDINAVICA, SUPPLEMENT. 1997;636:1-55
Neuropeptide Y Y1 receptor mechanisms in sympathetic vascular control.
Malmström RE
Other: ACTA PHYSIOLOGICA. 1995;155(3):329-330
Endogenous NPY acting on the Y1 receptor accounts for the long-lasting part of the sympathetic contraction in guinea-pig vena cava: evidence using SR 120107A.
Malmström RE; Lundberg JM
Visa fler

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI